Indication

Treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Filgotinib may be used as monotherapy or in combination with methotrexate (MTX).

Medicine details

Medicine name:
filgotinib (Jyseleca)
SMC ID:
SMC2365
Pharmaceutical company
Gilead Sciences Ltd
BNF chapter
Musculoskeletal and joint diseases
Submission type
Full
Publication due date:
13 September 2021
SMC meeting date:
03 August 2021
Patient group submission deadline:
05 July 2021